Immunology Drugmaker Electra Opens Flat After Upsized US IPO
THE SO WHAT
Electra Therapeutics raising $350m in an upsized IPO but trading flat suggests public markets will fund late-stage biotech, but without the 2021-style pop. Biotech operators should plan for capital access with muted aftermarket enthusiasm—story and pipeline depth matter more than listing optics.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureSoftBank agrees to acquire Robotics and AI Institute
SoftBank consolidating a research-heavy robotics and AI asset under CFIUS review shows frontier autonomy is now squarely in the national-interest bucket. If your roadmap depends on cross-border capital or talent in advanced robotics, assume more friction and longer timelines on strategic deals.
Startups & VentureUK Sovereign AI Fund in talks to back £500m raise for drug discovery startup
If the UK’s sovereign AI vehicle is anchoring a £500m raise into drug discovery, national AI strategy is moving from chips and models into domain-specific IP. Biotech operators should expect more state-backed AI competitors and tighter competition for top applied ML talent.
Startups & VentureManus seeks $4B valuation in new $500M fundraise as it resumes independent ops
A $4B target valuation and $500M raise for Manus, post-terminated merger, shows capital still believes in independent AI platforms rather than pure acqui-hires. If you’re a mid-stage AI company, this is a green light to pursue scale on your own terms—but expect investors to push hard on defensibility and unit economics.
Startups & VentureFamily offices are clamoring for AI investments
Family offices piling into AI is fresh capital but also a classic late-cycle signal—check whether your round is being priced on fundamentals or fear of missing the next OpenAI. Founders should use this window to strengthen balance sheets, not to overextend burn on speculative bets.